Jiangxi-based pharmaceutical manufacturer selling generic drugs in China.
Jiangxi-based pharmaceutical manufacturer selling generic drugs in China.
Moat: none
Headquarters: Jiangxi, China · Employees: 1,663
Size Jiangxi Fushine Pharmaceutical (300497.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.02B, the 2118th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥13.02 on 18 Nov 2026.
Performance Over six months the shares fell 23.1%, against -10.6% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 102.6% over the last twelve months (peer median +5.9%); the operating margin is 24.0% (peer median 8.7%).
Valuation It trades at 9.9× forward earnings against a peer median of 20.6× (3rd cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is -4%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.2 points above its cost of capital (8.3% WACC).
Next results Next results expected around 3 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.97B | CN¥1.18B | CN¥1.17B | CN¥1.61B | CN¥1.64B |
| Revenue growth | — | +1% | -27% | -2% | — |
| Gross profit | CN¥905M | CN¥151M | CN¥19.9M | CN¥108M | CN¥244M |
| EBITDA | n/a | CN¥146M | -CN¥22.0M | -CN¥16.3M | CN¥60.0M |
| Net income | CN¥411M | -CN¥55.0M | -CN¥272M | -CN¥201M | -CN¥141M |
| Free cash flow | CN¥60.0M | -CN¥161M | CN¥46.9M | -CN¥306M | -CN¥579M |
| Capital expenditure | CN¥142M | CN¥225M | CN¥142M | CN¥242M | CN¥459M |
| Total debt | CN¥1.63B | CN¥1.75B | CN¥1.95B | CN¥1.98B | CN¥1.79B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300497.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.7% | -5.0% | 9th lowest of 21 |
| 6-month return | -23.1% | -10.6% | 4th lowest of 21 |
| Distance from 52-week high | -46.1% | -32.1% | 6th lowest of 21 |
| Revenue growth (TTM) | +102.6% | +5.9% | 2nd highest of 19 |
| Operating margin | 24.0% | 8.7% | 4th highest of 19 |
| Forward P/E | 9.9× | 20.6× | 3rd cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | 7.5% | 2.5% | 3rd most demanding of 14 |
| Growth delivered (Del g) | -4.5% | +7.7% | 4th lowest of 14 |
| Hurdle (Req g minus delivered) | +12.0 pp | -3.6 pp | 3rd most demanding of 14 |
| ROIC minus cost of capital | +4.2 pp | +0.1 pp | 6th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.02B | -23% | +103% | 24% | 9.9× | 7.5% | -4.5% |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.03B | -33% | -2% | 13% | 24.6× | 4.4% | +7.7% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.02B | +1% | +27% | 4% | 21.4× | 4.3% | +3.5% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -10% | +7% | 9% | 7.7× | -0.3% | +12.1% |
| Renhe Pharmacy 000650.SZ | China | $1.01B | -12% | -7% | 14% | 16.9× | -10.7% | -7.0% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -11% | +31% | -7% | 4.7× | -6.5% | -7.7% |
| SAWAI 4887.T | Japan | $1.01B | -18% | +2% | 9% | 12.0× | n/a | n/a |
| Savara SVRA | United States | $1.04B | -7% | n/a | n/a | n/a | n/a | n/a |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.04B | +33% | +5% | 24% | 10.5× | -5.6% | +12.7% |
| Shandong Lukang Pharmaceutical 600789.SS | China | $1.05B | -18% | -7% | 3% | n/a | 2.5% | +6.5% |
| Shanghai Yizhong Pharmaceutical 688091.SS | China | $1.00B | -49% | +32% | 14% | n/a | n/a | n/a |
| Aurisco Pharmaceutical 605116.SS | China | $1.00B | -23% | +3% | 25% | 13.6× | -2.0% | +18.7% |
| Shanghai InnoStar Bio-tech 688710.SS | China | $1,000M | +17% | +24% | 6% | 59.3× | 12.7% | +19.4% |
| Blue Jet Healthcare BLUEJET.NS | India | $1.05B | +19% | -7% | 28% | 30.6× | 40.8% | +13.8% |
| Everest Medicines 1952.HK | Hong Kong | $1.05B | -20% | +193% | -5% | 23.2× | n/a | n/a |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $989M | -9% | +8% | 7% | 19.8× | 2.3% | +1.8% |
| Aarti Pharmalabs AARTIPHARM.NS | India | $984M | +44% | +13% | 18% | n/a | n/a | n/a |
| InventisBio 688382.SS | China | $982M | -47% | -61% | -563% | n/a | 6.5% | -60.6% |
| Chongqing Taiji Industry (Group) 600129.SS | China | $982M | -20% | -4% | 2% | 69.8× | n/a | n/a |
| Seaport Therapeutics SPTX | United States | $980M | +16% | n/a | n/a | n/a | n/a | n/a |
| Procter & Gamble Health PGHL.NS | India | $979M | +3% | +13% | 31% | 24.5× | 5.6% | +9.3% |